<?xml version="1.0" encoding="UTF-8"?>
<p>At present, chemotherapy with the combination of pyrimethamine and sulfadiazine followed by azithromycin, clindamycin, atovaquone, etc., is considered as the preferred treatment for toxoplasmosis; however, studies in recent years have demonstrated that these drugs are associated with some side effects such as osteoporosis, and teratogenic effects mostly in immune-compromised patients [
 <xref rid="B5-molecules-26-00819" ref-type="bibr">5</xref>,
 <xref rid="B6-molecules-26-00819" ref-type="bibr">6</xref>]. Atovaquone, a hydroxynaphthoquinone derivative, has potent activity against tissue cysts through the blocking respiratory chain of the 
 <italic>Toxoplasma</italic>; therefore, it is broadly used for in vivo activity against 
 <italic>T. gondii</italic> during both infection stages [
 <xref rid="B7-molecules-26-00819" ref-type="bibr">7</xref>].
</p>
